

Berotrastat for the prophylaxis of hereditary angioedema – Outcomes in the United Kingdom

Manisha Ahuja¹, Anthony Dorr², Eniola Bode³, Anne Pacita Rosillo Boulton⁴, Matthew Buckland⁵, Samuel Chee⁶, Claire Dalley⁷, Sarah Denman³, Anjali Ekbote⁸, Shuayb Elkhaila⁶, Tariq El-Shanawany⁹, Efrem Eren¹⁰, Archana Herwadkar¹¹, Tomaz Garcez⁶, Harichandana Ghanta¹⁰, Alexandros Grammatikos¹², Sofia Grigoriadou⁵, Rashmi Jain¹³, Lorena Lorenzo⁵, Ania Manson⁴, Emily Moon⁶, Sai Murng¹⁴, Aveen Murphy⁵, Leman Mutlu⁸, Nicholas Peters¹³, Kavitha Sooriyakumar⁸, Catherine Stroud¹, Katie Townsend⁵, Patrick Yong¹⁵, and Sorena Kiani-Alikhan⁵

¹Royal Victoria Infirmary

²King's College Hospital NHS Foundation Trust

³Leeds Teaching Hospitals NHS Trust

⁴Cambridge University Hospitals NHS Foundation Trust

⁵Barts Health NHS Trust

⁶Manchester University NHS Foundation Trust

⁷Gloucestershire Royal Hospital

⁸University Hospitals Birmingham NHS Foundation Trust

⁹Cardiff and Vale University Health Board

¹⁰University Hospital Southampton NHS Foundation Trust

¹¹Salford Royal NHS Foundation Trust

¹²North Bristol NHS Trust

¹³Oxford University Hospitals NHS Foundation Trust

¹⁴Epsom and Saint Helier University Hospitals NHS Trust

¹⁵Frimley Health NHS Foundation Trust

June 8, 2022

Hosted file

Berotrastat Article Allergy June 2022.docx available at <https://authorea.com/users/487728/articles/572163-berotrastat-for-the-prophylaxis-of-hereditary-angioedema-outcomes-in-the-united-kingdom>